Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
22 June 2023 | Story Boitumelo Mokheseng | Photo Supplied
Boitumelo Mokheseng
Boitumelo Mokheseng is a Presidential Youth Employment Initiative (PYEI) Intern in the Qwaqwa Campus Health and Wellness Centre.

The University of the Free State (UFS) is celebrating Youth Month by showcasing the positive influence of the institution on career development. As part of this initiative, we are sharing the stories of UFS alumni who are now working at the university.

Boitumelo Mokheseng, Presidential Youth Employment Initiative (PYEI) Intern in the Qwaqwa Campus Health and Wellness Centre, shares her UFS journey:

Q: Year of graduation from the UFS:

A: 2021.

Q: Qualification obtained from the UFS:

A: Bachelor of Administration.

Q: Date of joining the UFS as a staff member:

A: March 2023.

Q: Initial job title and current job title:

A: PYEI intern in the Qwaqwa Campus Health and Wellness Centre.

Q: How did the UFS prepare you for the professional world?

A: The University of the Free State (UFS) propelled me towards the career path I had always aspired to. The comprehensive education I received not only equipped me with the necessary skills for the workplace, but also fostered a problem-solving mindset that was ingrained in us from our undergraduate years.

Q: What are your thoughts on transitioning from a UFS alumnus to a staff member?

A: The transition from being a UFS student to a staff member has been wonderful, even though challenging, because now I get to feel the pressure that the clinic staff felt while I was a student. For instance, when visiting the clinic before, I didn’t understand why there are long queues, why we are not assisted in time; since I’m the one assisting the students with the booking systems and making sure they get to the consulting rooms, I now understand how things work.

Q: Any additional comments about your experience?

A: Working here at the UFS has been a dream come true. I am fascinated daily by meeting up with inspiring people who motivate me to do better in life, and I keep learning new things. The experience so far is good; I have acquired new skills, moved from office work and got involved in campaigns such as First Things First where I can engage more with students and meet the different stakeholders from the health department. I’m thankful for the great opportunity the university has given me to be part of it as a staff member – no longer a student.

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept